BPC-157
BPC-157
---
BPC-157 (Pentadecapeptide) | 10 mg
Manufactured by BioChain USA · United States of America
For research use only. Not for human or animal consumption. This compound is sold exclusively for in vitro research, laboratory, and analytical purposes by BioChain USA. It is not a drug, supplement, or therapeutic product of any kind.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide derived from a partial sequence of a protein identified in human gastric juice. Also referred to as pentadecapeptide BPC-157, it is studied exclusively in preclinical research settings — primarily cell culture and animal models — where investigators examine its behavior across several signaling contexts.
In published research, BPC-157 is used as a tool to study tissue repair signaling pathways, vascular and angiogenesis-related biology, connective tissue and tendon cell models, and gastrointestinal mucosal integrity frameworks. Its appearance across multiple preclinical research disciplines has made it a commonly referenced peptide in the experimental biology literature.
Chemical Reference Data
| Molecular Formula | C62H98N16O22 |
|---|---|
| Molecular Weight | ~1,419.5 g/mol |
| Peptide Length | 15 amino acids |
| Structural Classification | Synthetic pentadecapeptide — partial sequence of human gastric juice protein BPC |
| Also referenced as | Pentadecapeptide BPC-157; Body Protection Compound 157 |
| CAS Number | 137525-51-0 |
Structural Context
BPC-157 is a linear 15-amino acid peptide produced by chemical synthesis. In the published literature, its structural origin is consistently described as a partial sequence derived from a larger protein fraction identified in human gastric juice, which is discussed as context for why early research interest centered on gastrointestinal model systems.
Key structural characteristics noted in the research literature include:
- Short peptide length: At 15 amino acids, BPC-157 is a relatively compact peptide. Short peptide length is discussed in some research contexts as relevant to membrane permeability and distribution within in vitro model systems.
- Stability in research settings: BPC-157 is described in some publications as exhibiting stability under standard laboratory conditions compared with endogenous peptides of similar length, which is cited as one rationale for its selection as a research probe in controlled experimental designs.
- No assigned single receptor target: Unlike receptor-targeting peptides such as GLP-1 analogues or melanocortin ligands, BPC-157 does not have a single well-characterized receptor binding target described in the literature. Research discussions focus on downstream pathway readouts — including VEGF signaling, FAK/paxillin activation, and ERK pathway activity — as observed experimental endpoints rather than a defined receptor binding mechanism.
BioChain USA does not make medical claims. Research context does not equal clinical outcome data.
Research Applications
BPC-157 is used as a research tool to investigate:
- Tissue repair signaling models — wound closure assay designs, histological endpoint analysis in injury model frameworks, collagen-related structure development, and vascular network formation markers
- Angiogenesis and vascular biology — endothelial cell proliferation and migration assays, VEGF pathway interaction studies, and blood vessel formation markers in preclinical models
- Tendon fibroblast and connective tissue models — cell outgrowth and migration assays, cytoskeletal organization markers, FAK and paxillin pathway activation readouts, and oxidative stress response studies
- Gastrointestinal mucosal integrity research — ulceration models, mucosal injury assays, blood flow markers, and recovery endpoint measurements in GI tissue model systems
- Broader preclinical exploratory models — inflammation signaling panels, organ injury models, and additional experimental frameworks as described in hypothesis-generating preclinical literature
Specific applications depend on the researcher's study design and objectives.
Key Research Themes in the Literature
1. Tissue Repair Signaling — Wound Model Research
The largest body of BPC-157 literature addresses tissue repair in preclinical wound models. Published studies typically compare control and BPC-157 exposure conditions and evaluate histological outcomes, with reported observations focused on markers associated with tissue rebuilding — including collagen-related structure development and vascular network formation in wound beds.
Signaling pathway discussions in this literature commonly reference:
- VEGF-related signaling as a proposed vascular component of observed tissue repair markers
- ERK (extracellular signal-regulated kinase) pathway activity as a downstream proliferation and survival signaling readout
- Growth factor pathway interactions framed as possible mechanistic explanations for observed tissue remodeling endpoints
These are study-level observations from published research — not product claims made by BioChain USA.
2. Vascular Support Pathways — Angiogenesis-Related Models
Several published studies frame BPC-157 in the context of processes related to blood vessel formation and endothelial cell behavior. Research in this area commonly uses in vitro endothelial assay systems, with reported observations including:
- Endothelial cell proliferation rate changes in treated vs. control conditions
- Endothelial cell migration in wound scratch and transwell assay designs
- Tube formation assay readouts in Matrigel-based angiogenesis model systems
- VEGF pathway expression and receptor activation as measured signaling endpoints
Published discussions in this area frame vascular effects as mechanistically relevant to wound healing and tissue repair observations reported in the same literature. BioChain USA presents this as research literature context only.
3. Tendon and Ligament Research Models
BPC-157 is frequently referenced in tendon and connective tissue cell biology research, where investigators use tendon fibroblast cell lines or primary tendon-derived cells to measure cellular behavior in controlled experimental conditions.
Commonly reported observations in this research theme include:
- Cell outgrowth and directional migration in explant and migration assay designs
- Survival signaling under oxidative stress conditions — with Akt and FAK pathway activation discussed as protective signaling readouts
- Cytoskeletal organization and motility markers, including lamellipodia formation and cytoskeletal architecture quantification
- FAK (focal adhesion kinase) and paxillin activation — described in the literature as adhesion and motility pathway endpoints, with pathway activation (rather than total protein level) cited as the observed experimental change
BioChain USA does not represent these published findings as claims about tendon outcomes in living systems.
4. Gastrointestinal Integrity Models
Because BPC-157's structural origin is described as gastric-derived, it is frequently used as a research probe in gastrointestinal model systems. Publications in this area commonly examine GI mucosal biology in cell culture and animal model designs.
Research observations described in the published GI literature include:
- Mucosal injury model endpoints — epithelial integrity markers and barrier function readouts
- Ulceration model comparisons — BPC-157 vs. control and vs. known growth factors in ulcer healing assay systems
- Blood flow and microvascular markers in GI tissue perfusion models
- Functional recovery endpoint measurements in GI injury model frameworks
Some publications compare BPC-157 behavior to known growth factors (including EGF) in mucosal repair contexts. BioChain USA presents these as research literature observations only.
5. Broader Preclinical Exploratory Research
A portion of the BPC-157 literature extends into additional experimental model categories beyond the core tissue repair and GI themes. These areas are typically framed as hypothesis-generating or exploratory in the published literature, and include:
- Organ injury models — liver, kidney, and other organ system preclinical frameworks where tissue damage markers and recovery endpoints are measured
- Inflammation signaling panels — cytokine marker readouts and NF-κB pathway activity in inflammatory condition cell models
- Neuro-related model systems — limited published literature describing exploratory use in neuronal cell assay designs, typically framed as preliminary or observational
These are exploratory research contexts described in published literature. BioChain USA makes no claims about organ, inflammatory, or neurological outcomes.
Certificate of Analysis (COA)
- COA provided where available for the specific batch shipped.
- The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment. Analytical documentation may include HPLC and mass spectrometry data where available.
- COA information is batch-specific and is not interchangeable between lots.
Storage and Handling
General peptide handling guidance for research use:
- Store in a cool, dry, dark environment.
- Protect from light — lyophilized peptides can degrade under UV exposure.
- Follow standard peptide handling protocols to minimize moisture exposure.
- Avoid repeated open-close cycles that introduce humidity to the lyophilized material.
- If working with reconstituted solutions, aliquot to minimize freeze-thaw cycling, which can affect peptide integrity over time.
BioChain USA does not provide instructions for human or animal administration.
Frequently Asked Questions
Is this product for human use?
No. BPC-157 is not approved or intended for human or veterinary use in this context. It is sold exclusively for in vitro research, laboratory, and analytical purposes. It is not a drug, supplement, or therapeutic product of any kind.
What is BPC-157 used for in research?
Common research applications include tissue repair signaling model studies, wound biology assay designs, endothelial cell and angiogenesis assay systems, tendon fibroblast cell models, gastrointestinal mucosal integrity research, and broader exploratory preclinical model frameworks. Specific applications depend on the researcher's study design and objectives.
Do you provide dosing instructions or administration protocols?
No. BioChain USA does not provide dosing guidance, administration instructions, or protocols for human or animal use. Researchers are responsible for designing in vitro study protocols appropriate to their applications and institutional requirements.
Do you provide a Certificate of Analysis (COA)?
Yes, where available. COAs are batch-specific documents reflecting the analytical testing and purity data for that particular lot. The COA included with your order is the authoritative reference for that batch. Availability may vary by lot.
Compliance and Disclaimers
- Sold for research, laboratory, or analytical purposes only.
- Not intended to diagnose, treat, cure, or prevent any disease or condition.
- Not for human or animal consumption.
- Purchaser assumes full responsibility for compliance with all applicable local, state, and federal regulations governing the purchase and use of research compounds.